Daiichi Sankyo’s Asubio Pharma Allocates $102 Million To Research Plant
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo subsidiary Asubio Pharma plans to spend $102 million to build a research facility near Kobe. Asubio planned the facility to be located near the world's fastest supercomputer expected to be available next year. The Daiichi Sankyo subsidiary already specializes in bio-based treatments for various ailments. Its facility is to be among one of 130 drug research and development facilities on Kobe's Port Island. (Click here for more - a subscription may be required
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.